Trials / Recruiting
RecruitingNCT07432633
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
A Phase 1/2 Study of [18F]FPyQCP for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 71 (estimated)
- Sponsor
- Blue Earth Diagnostics · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
Conditions
- Colorectal Cancer
- Epithelial Ovarian Cancer
- Gastric Cancer
- Invasive Lobular Breast Carcinoma
- Pancreatic Ductal Adenocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]FPyQCP | positron emission tomography (PET)/computed tomography (CT) imaging |
Timeline
- Start date
- 2026-03-18
- Primary completion
- 2028-01-31
- Completion
- 2028-01-31
- First posted
- 2026-02-25
- Last updated
- 2026-03-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07432633. Inclusion in this directory is not an endorsement.